Abstract:Diabetic nephropathy (DN) is a common and serious microvascular complication of diabetes mellitus (DM). According to epidemiological studies, more than 425 million people worldwide are currently affected by diabetes. If no action is taken, more and more people with diabetes worldwide will rise to 629 million by 2045. [ 1 ] As the prevalence of diabetes has increased, the incidence of DN has increased rapidly. Being expected to 30% to 40% of diabetic patients develop DN, finally, the one third of DN patients develop end-stage renal disease. Currently, it has been shown that the mechanism of DN is the result of a combination of factors such as glucose metabolism disorders, changes in glomerular hemodynamics, inflammatory reactions, cytokines, endothelial damage, oxidative stress, ischemia and hypoxia, and genetic susceptibility. Chronic renal hypoxia, caused by various factors such as hyperglycemia, endothelial damage, and inflammatory responses, is one of the main causes of the occurrence and development of DN. Hypoxia is considered as an etiological factor in the progression of renal injury. HIF1α is a major transcription factor that transduces an array of cellular processes to let the cells adapt to hypoxic injury. Therefore, a sustained increase in HIF1α is a major adaptive stimulus to the hypoxic conditions. [ 2 ] By regulating its target ZEB2 gene (Zinc finger E-box-binding homeobox 2), it affects pathological and physiological processes such as glucose, energy metabolism, inflammation, and plays an essential role in the occurrence and development of DN. [ 3–5 ] There is a growing body of evidence that hypoxia can cause kidney damage, inflammatory reactions, loss of podocytes and abnormal function, and reduced glomerular filtration rates leading to proteinuria. If not intervened in a timely manner at an early stage, this is a huge financial burden on society. [ 6 ] Western medications are used to treat DN by regulating blood glucose, blood lipid levels and blood pressure. Early medical studies have shown that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (angiotensin II receptor blockers) as first-line treatment for DN can reduce proteinuria, The role of delaying the progress of renal dysfunction. [ 7 ] However, the side effects of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers limit the use of these drugs. Therefore, the search for safe and effective therapies for DN is of great urgency.

Signal Transduction Pathway in Diabetic Nephropathy 1 . MAPK signaling pathway in DN

Research Progress in Signalling Pathway in Diabetic Nephropathy.

Diabetic Nephropathy: Focusing on Pathological Signals, Clinical Treatment, and Dietary Regulation.

Modulation of MAPK Signaling Pathway by Traditional Chinese Medicine for the Treatment of Diabetic Renal Fibrosis

The Wnt Signaling Pathway in Diabetic Nephropathy

The connection between GRKs and various signaling pathways involved in diabetic nephropathy

An Overview of the Posttranslational Modifications and Related Molecular Mechanisms in Diabetic Nephropathy

TGF-β signaling in diabetic nephropathy: An update

Research Progress on Regulation of Nrf2/Keap1 Signaling Pathway by Traditional Chinese Medicine in the Treatment of Diabetic Nephropathy

The regulatory effect and mechanism of traditional Chinese medicine on the renal inflammatory signal transduction pathways in diabetic kidney disease: A review

S1PR2/Wnt3a/RhoA/ROCK1/β-catenin signaling pathway promotes diabetic nephropathy by inducting endothelial mesenchymal transition and impairing endothelial barrier function

G protein-coupled receptors: potential therapeutic targets for diabetic nephropathy.

Exploring the mechanism of Dahuang-Tusizi drug pair in the treatment of diabetes nephropathy based on network pharmacology and immune infiltration analysis

Common gene signatures and molecular mechanisms of diabetic nephropathy and metabolic syndrome

The Role of Chemokines and Chemokine Receptors in Diabetic Nephropathy

Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management

Role and Mechanism of NUP160-regulated Autophagy in Pathogenesis of Diabetic Nephropathy

Integrated Bioinformatics and Clinical Correlation Analysis of Key Genes, Pathways, and Potential Therapeutic Agents Related to Diabetic Nephropathy

Identification of Hub Genes Involved in Tubulointerstitial Injury in Diabetic Nephropathy by Bioinformatics Analysis and Experiment Verification

mTOR pathway: A key player in diabetic nephropathy progression and therapeutic targets

Research Progress on Mechanism of Podocyte Depletion in Diabetic Nephropathy